Sara Nunnery, MD, director of breast cancer research at Tennessee Oncology, outlines key considerations when deciding whether to offer trastuzumab deruxtecan to patients with HER2-low or HER2-ultralow metastatic breast cancer. Dr. Nunnery explains how clinical factors, treatment setting (IV vs oral), and patient preferences around quality of life all play a role in determining the ideal candidate for this therapy.
Breast Cancers Today
Breast Cancers Today features breaking news, commentary, expert interviews, and more updates to inform healthcare professionals on the latest research and best clinical practices in the breast cancer space.
Advertisement
Latest News
Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer.
Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer.
Dr Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade.
Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
Advertisement
Expert Interviews
Advertisement
Editorial Board
Stephanie L. Graff, MDEditor | Director of Breast Oncology, Brown University Health Cancer Institute
Rebecca Shatsky, MDEditor | Associate Professor of Medicine, Moores Cancer Center at the University of California, San Diego
Maryam Lustberg, MD, MPHEditor | Director of the Center for Breast Cancer, Smilow Cancer Hospital and Yale Cancer Center
Erika P. Hamilton, MDEditor | Director of Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute
Sarah Sammons, MDEditor | Associate Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.